Hemophilia Inhibitor Previously Untreated Patient Study

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Hemophilia A
Interventions
DRUG

FVIII concentrate

usual treatment as directed by treating physician

Trial Locations (17)

1105

Emma Children's Hospital AMC, Amsterdam

10065

Cornell University, New York

15213

Hemophilia Center of Western Pennsylvania, Pittsburgh

20122

Angelo Bianchi Bonomi Hemophilia & Thrombosis Center, Milan

27599

University of North Carolina at Chapel Hill, Chapel Hill

30322

Emory University, Atlanta

40536

University of Kentucky, Lexington

45229

Cincinnati Children's Hospital, Cincinnati

46260

Indiana Hemophilia and Thrombosis Center, Indianapolis

70112

Tulane University, New Orleans

75235

North Texas Comprehensive Hemophilia Center, Dallas

77030

Baylor College of Medicine, Houston

University of Texas Health Science Center-Houston, Houston

84108

Intermountain Hemophilia and Thrombosis Center, Salt Lake City

Unknown

University of Oregon, Portland

A-1090

Medical University of Vienna, Vienna

Se-205 02

Malmo Centre for Thrombosis and Haemostasis, Malmo

All Listed Sponsors
collaborator

Rho, Inc.

INDUSTRY

collaborator

Baxter Healthcare Corporation

INDUSTRY

lead

The University of Texas Health Science Center, Houston

OTHER

NCT01652027 - Hemophilia Inhibitor Previously Untreated Patient Study | Biotech Hunter | Biotech Hunter